14 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
responsible for vision. The vision loss caused by GA severely impairs independence and quality of life by making it difficult to participate in daily
424B5
6i39vm9e vz1qsmly4
7 Mar 19
Prospectus supplement for primary offering
4:28pm
424B5
43pzjbruv4xl0
6 Mar 19
Prospectus supplement for primary offering
4:07pm
10-K
psb1b555
19 Mar 18
Annual report
12:00am
- Prev
- 1
- Next